A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity

• ClinicalTrials.gov Identifier: NCT04707313
• Recruitment Status: Completed
• First Posted: January 13, 2021
• Last Update Posted: October 26, 2023
• Sponsor: Pfizer
• Information provided by (Responsible Party): Pfizer

Tracking Information

• First Submitted Date: January 11, 2021
• First Posted Date: January 13, 2021
• Last Update Posted Date: October 26, 2023
• Actual Study Start Date: January 29, 2021
• Actual Primary Completion Date: September 13, 2023 (Final data collection date for primary outcome measure)
• Current Primary Outcome Measures (submitted: October 28, 2022): Percent change from baseline in body weight [ Time Frame: Cohorts 1 and 2: Baseline and Week 26; Cohort 3: Baseline and Week 32 ]
• Original Primary Outcome Measures (submitted: January 11, 2021): Percent change from baseline in body weight [ Time Frame: Baseline, Week 26 (End of Treatment) ]

Current Secondary Outcome Measures (submitted: October 28, 2022)

• Body weight loss of greater than or equal to 5% [ Time Frame: Cohorts 1 and 2: Baseline and Week 26; Cohort 3: Baseline and Week 32 ]
• Percent change from baseline in body weight [ Time Frame: Cohorts 1 and 2: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 18 and 22; Cohort 3: Baseline, Week 4, 8, 12, 16, 20, 24 and 28 ]
• Absolute change from baseline in waist circumference [ Time Frame: Cohorts 1 and 2: Baseline and Week 26; Cohort 3: Baseline and Week 32 ]
• Absolute change from baseline in waist-to-hip ratio [ Time Frame: Cohorts 1 and 2: Baseline and Week 26; Cohort 3: Baseline and Week 32 ]
• Absolute change from baseline in hemoglobin A1c [ Time Frame: Cohorts 1 and 2: Baseline, Week 16 and 26; Cohort 3: Baseline, Week 16, 24 and 32 ]
• Absolute change from baseline in fasting plasma glucose [ Time Frame: Cohorts 1 and 2: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 18, 22 and 26; Cohort 3: Baseline, Week 4, 8, 12, 16, 20, 24, 28 and 32 ]
• Incidence of treatment emergent adverse events (AEs and SAEs) [ Time Frame: Cohorts 1 and 2: Baseline up to Week 31; Cohort 3: Baseline up to Week 37 ]
• Incidence of treatment emergent clinically significant laboratory abnormalities [ Time Frame: Cohorts 1 and 2: Baseline up to Week 28; Cohort 3: Baseline up to Week 34 ]
• Incidence of treatment emergent clinically significant vital sign abnormalities [ Time Frame: Cohorts 1 and 2: Baseline up to Week 28; Cohort 3: Baseline up to Week 34 ]
• Incidence of treatment emergent clinically significant electrocardiogram (ECG) abnormalities [ Time Frame: Cohorts 1 and 2: Baseline up to Week 28; Cohort 3: Baseline up to Week 34 ]
• Number of participants with categorical scores on the Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: Cohorts 1 and 2: Baseline up to Week 28; Cohort 3: Baseline up to Week 34 ]
• Number of participants with categorical scores on the Patient Health Questionniare-9 (PHQ-9) [ Time Frame: Cohorts 1 and 2: Baseline up to Week 28; Cohort 3: Baseline up to Week 34 ]

Original Secondary Outcome Measures (submitted: January 11, 2021)

• Body weight loss of greater than or equal to 5% [ Time Frame: Baseline, Week 26 (End of Treatment) ]
• Percent change from baseline in body weight [ Time Frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 18 and 22 ]
• Absolute change from baseline in waist circumference [ Time Frame: Baseline, Week 26 (End of Treatment) ]
• Absolute change from baseline in waist-to-hip ratio [ Time Frame: Baseline, Week 26 (End of Treatment) ]
• Absolute change from baseline in hemoglobin A1c [ Time Frame: Baseline, Week 16 and 26 ]
• Absolute change from baseline in fasting plasma glucose [ Time Frame: Baseline, Week 2, 4, 6, 8, 10, 12, 16, 18, 22 and 26 ]
• Incidence of treatment emergent adverse events (AEs and SAEs) [ Time Frame: Baseline up to Week 31 ]
• Incidence of treatment emergent clinically significant laboratory abnormalities [ Time Frame: Baseline up to Week 28 ]
• Incidence of treatment emergent clinically significant vital sign abnormalities [ Time Frame: Baseline up to Week 28 ]
• Incidence of treatment emergent clinically significant electrocardiogram (ECG) abnormalities [ Time Frame: Baseline up to Week 28 ]
• Number of participants with categorical scores on the Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: Baseline up to Week 28 ]
• Number of participants with categorical scores on the Patient Health Questionnaire-9 (PHQ-9) [ Time Frame: Baseline up to Week 28 ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
• Official Title: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06882961 ADMINISTRATION IN ADULTS WITH OBESITY

Brief Summary

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-06882961) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-06882961) to those of participants who take placebo (a look- alike substance that contains no active study medicine). The aim is to measure the body's response to the study medicine, including any changes in participants' body weight, waist and hip measurements, how well they tolerate the study medicine, and to measure levels of the study medicine in participants' blood.

This study is seeking participants who have obesity, who do not have diabetes and who have had a stable body weight and not participated in a formal weight loss program in the 90 days before the study. The study medicine or placebo will be taken as tablets by mouth 2 times a day (1 time in the morning and 1 time in the evening).

There are 3 groups of participants (called cohorts) in this study. For participants in Cohorts 1 and 2, total study participation will be about 9 months, with 15 planned study visits (14 visits to the study clinic and 1 telephone call). For participants in Cohort 3, total study participation will be about 10 months, with 21 planned study visits (12 visits to the study clinic and 9 telephone calls).

• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment
• Condition: Obesity

Intervention

• Drug: Placebo (Cohorts 1 and 2)
  4 matching placebo tablets taken twice daily
• Drug: PF-06882961 (Cohorts 1 and 2)
  Participants will be randomized to one of 5 active target dose levels (40, 80, 120, 160 or 200 mg BID) achieved through 1-week titration steps, or 3 active target dose levels (120, 160 or 200 mg BID) achieved through 2-week titration steps, taking 4 tablets twice daily
• Drug: Placebo (Cohort 3)
  2 matching placebo tablets taken twice daily
• Drug: PF-06882961 (Cohort 3)
  Participants will be randomized to one of 3 active target dose levels (80, 140 or 200 mg BID) achieved through 4-week titration steps, taking 2 tablets twice daily.

Study Arms

• Placebo Comparator: Placebo (Cohorts 1 and 2)
  Intervention: Drug: Placebo (Cohorts 1 and 2)
• Experimental: PF-06882961 40 milligrams (mg) twice daily (BID), 1-week titration (Cohort 1)
  The dose will be titrated with 1 week of dosing at each step to reach the target dose of 40 mg BID.
  Intervention: Drug: PF-06882961 (Cohorts 1 and 2)
• Experimental: PF-06882961 80 mg BID, 1-week titration (Cohort 1)
  The dose will be titrated with 1 week of dosing at each step to reach the target dose of 80 mg BID.
  Intervention: Drug: PF-06882961 (Cohorts 1 and 2)
• Experimental: PF-06882961 120 mg BID, 1-week titration (Cohort 1)
  The dose will be titrated with 1 week of dosing at each step to reach the target dose of 120 mg BID.
  Intervention: Drug: PF-06882961 (Cohorts 1 and 2)
• Experimental: PF-06882961 160 mg BID, 1-week titration (Cohort 1)
  The dose will be titrated with 1 week of dosing at each step to reach the target dose of 160 mg BID.
  Intervention: Drug: PF-06882961 (Cohorts 1 and 2)
• Experimental: PF-06882961 200 mg BID, 1-week titration (Cohort 1)
  The dose will be titrated with 1 week of dosing at each step to reach the target dose of 200 mg BID.
  Intervention: Drug: PF-06882961 (Cohorts 1 and 2)
• Experimental: PF-06882961 120 mg BID, 2-week titration (Cohorts 1 and 2)
  The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 120 mg BID.
  Intervention: Drug: PF-06882961 (Cohorts 1 and 2)
• Experimental: PF-06882961 160 mg BID, 2-week titration (Cohorts 1 and 2)
  The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 160 mg BID.
  Intervention: Drug: PF-06882961 (Cohorts 1 and 2)
• Experimental: PF-06882961 200 mg BID, 2-week titration (Cohorts 1 and 2)
  The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 200 mg BID.
  Intervention: Drug: PF-06882961 (Cohorts 1 and 2)
• Placebo Comparator: Placebo (Cohort 3)
  Intervention: Drug: Placebo (Cohort 3)
• Experimental: PF-06882961 80 mg BID, 4-week titration (Cohort 3)
  The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 80 mg BID.
  Intervention: Drug: PF-06882961 (Cohort 3)
• Experimental: PF-06882961 140 mg BID, 4-week titration (Cohort 3)
  The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 140 mg BID.
  Intervention: Drug: PF-06882961 (Cohort 3)
• Experimental: PF-06882961 200 mg BID, 4-week titration (Cohort 3)
  The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 200 mg BID.
  Intervention: Drug: PF-06882961 (Cohort 3)

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: October 5, 2023): 630
• Original Estimated Enrollment (submitted: January 11, 2021): 420
• Actual Study Completion Date: October 11, 2023
• Actual Primary Completion Date: September 13, 2023 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Participants with obesity, defined as a Body Mass Index greater than or equal to 30.0 kg/m2
• Stable body weight, defined as <5 kg change (per participant report) for 90 days before visit 1

Exclusion Criteria:

• Any condition possibly affecting drug absorption
• Current or prior diagnosis of Type 1 or Type 2 diabetes mellitus or secondary forms of diabetes
• History of myocardial infarction, unstable angina, arterial revascularization, stroke, heart failure, or transient ischemic attack within 6 months prior to visit 1
• Any malignancy not considered cured
• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 or suspected MTC
• History of acute pancreatitis within 180 days (6 months) prior to visit 1 or any history of chronic pancreatitis
• Symptomatic gallbladder disease
• Medical history or characteristics suggestive of genetic or syndromic obesity or obesity induced by other endocrinological disorders
• History of major depressive disorder or other severe psychiatric disorders within the last 2 years
• Any lifetime history of a suicide attempt
• Known medical history of active liver disease, including chronic active hepatitis B or C, or primary biliary cirrhosis
• Known history of HIV
• Supine blood pressure greater than or equal to 160 mmHg (systolic) or greater than or equal to 100 mmHg (diastolic)
• Clinically relevant ECG abnormalities
• Positive urine drug screen
• Participation in a formal weight reduction program within 90 days prior to visit 1

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 75 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Canada, Japan, Taiwan, United States

Administrative Information

• NCT Number: NCT04707313
• Other Study ID Numbers: C3421019; 2020-001312-19 ( EudraCT Number )
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: Yes
• Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
• URL: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests

• Current Responsible Party: Pfizer
• Original Responsible Party: Same as current
• Current Study Sponsor: Pfizer
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Pfizer CT.gov Call Center; Pfizer

• PRS Account: Pfizer
• Verification Date: October 2023